Sequencing in the fast lane
25 July 2012 
Feature
Phillip Broadwith gets up to speed with the latest developments in DNA sequencing technology
Illumina investment push
8 January 2013
Gene sequencing company Illumina has struck a $450 million (£280 million) deal to buy privately owned US firm Verinata Health, which specialises in non-invasive tests for early identification of foetal chromosomal abnormalities.
The deal follows the collapse of Roche’s $5.7 billion hostile bid for Illumina in early 2012 – which the company rejected. It also follows Illumina’s acquisition of BlueGnome, a University of Cambridge spinout that has developed a test for counting chromosomes in a cell.
Illumina will pay $350 million up front, plus up to $100 million in milestone payments.
Related Content
Illumina fends off Roche hostile bid
27 January 2012 News Archive
Roche aims to expand personalised medicine diagnostics by acquiring the gene sequencing leader
Most Read
Lab-on-a-chip rises to cola challenge
13 May 2013 Research
'Liquid fingerprinting' can 'taste' the difference between red wines, mineral waters and vodkas
Sugar solution to toxic gold recovery
15 May 2013 Research
The environmental legacy of salvaging gold from electronic waste can be dramatically cut using corn starch instead of cyanide
Most Commented
Congress says US needs a science laureate
14 May 2013 News and Analysis
New legislation proposes the appointment of a public champion for research
Step towards a spider venom vaccine
13 May 2013 Research
Engineered protein can be used to produce antivenoms and might provide long-lasting protection against bites